Remove 2024 Remove Compounding Remove Immunization
article thumbnail

V116 Well-Tolerated With Broad Immune Responses in Pneumococcal Vaccine-Naïve Older Adults

Pharmacy Times

The vaccine showed superior immune response for unique serotypes compared to PPSV23, with higher OPA titers.

article thumbnail

Implications of RFK Jr.’s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry

PharmaTech

s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. ACIP plays a foundational role in shaping immunization policy in the US. Kennedy Jr.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

From Pharmacy Counters to Classrooms: Building Confidence in Back-to-School Vaccinations

Pharmacy Times

Parental vaccine hesitancy, fueled by misinformation and logistical barriers, contributes to lower immunization rates and increased exemption rates. Pharmacies enhance vaccine access and education, offering convenient vaccination opportunities and personalized counseling to counter hesitancy.

article thumbnail

Exploring Natural Compounds: Prunus Armeniaca, Bee Venom, and Bioactives in Breast Cancer Therapy

Pharmacy Times

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

article thumbnail

RSV Vaccine Uptake Remains Low Among US Adults Aged 60 Years and Older

Pharmacy Times

Arexvy was the first RSV vaccine approved by the FDA in May 2023 for adults aged 60 years and older, followed by Abrysvo, also in May 2023, and mRESVIA in May 2024; however, their indications have been updated since their initial approval.

article thumbnail

Expanding Pneumococcal Vaccinations to Healthy Adults Aged 50 to 64 Years Offers Significant Health, Economic Benefits

Pharmacy Times

Prior to October 2024, the Advisory Committee on Immunization Practices (ACIP) recommended use of a PCV only for all adults aged 65 years and older, including those aged 19 to 64 years with risk conditions for pneumococcal disease.

article thumbnail

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Pharmacy Times

Further, the incidence, severity, and kinetics of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome with CD20 × CD3 TCEs may vary depending on the B-cell lymphoma subtype and the combination partners used, which is a notable consideration for oncology pharmacists when operationalizing these therapies.